Navigation Links
23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases
Date:1/28/2009

DAVOS, Switzerland, Jan. 28 /PRNewswire/ -- 23andMe, Inc., an industry leader in personal genetics, and mondoBIOTECH AG, a Swiss research company dedicated to the development of treatments for rare diseases, today announced at the World Economic Forum in Davos, Switzerland, that they are collaborating to advance research of rare diseases. The announcement marks the return of the companies to the World Economic Forum, where they both were recognized as Technology Pioneers in 2008.

23andMe and mondoBIOTECH will work together to facilitate research of the genetic bases of rare and potentially fatal diseases, such as Pulmonary Arterial Hypertension, Sarcoidosis, and Pulmonary Fibrosis, the genetics of which are poorly understood. mondoBIOTECH will identify individuals suffering from certain rare diseases and sponsor their enrollment in the 23andMe Personal Genome Service(TM). Researchers then will be able to study the genetic information collected, along with any phenotypic information provided, in clinical trials, to understand potential causes of these diseases. 23andMe will coordinate genome-wide association studies for mondoBIOTECH affiliates using its research infrastructure and bioinformatics expertise.

The Illumina DNA Analysis technology used by 23andMe is the world's leading technology for genome-wide association studies and has the unique capability to include custom markers. This feature enabled 23andMe to select SNPs (single nucleotide polymorphisms), or variants that provide coverage of genes associated with drug response, information that is proving to be critical for the development of personalized medicine. In addition to having over half a million markers available for disease research, these "pharmacogenetic" indicators included in the 23andMe dataset could provide invalua
'/>"/>

SOURCE 23andMe, Inc.; mondoBIOTECH AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. 23andMe Announces Breast Cancer Initiative
2. The World Economic Forum Announces Technology Pioneers 2008: Mondobiotech Selected
3. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
6. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
9. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
11. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... 24, 2015  Champions Oncology (OTC-BB: CSBR), a company ... services to personalize the development and use of oncology ... operational results for the fourth quarter and fiscal year ... 2015, before market open. The company will ... day at 9:00 a.m. EDT (6:00 a.m. PDT). To ...
(Date:7/24/2015)... , July 24, 2015 , ... , Expands product offering for chronic kidney disease ... needs in diabetes-related complications and dermatology , Increases ... (HKEX:1530) ("3SBio" or ,the Company"), a leading ... manufacturing and marketing biopharmaceutical products, today announced that it ...
(Date:7/23/2015)... ... , ... Science and technology continue to improve all aspects of brain tumor ... to Susan Chang, MD, director of the Division of Neuro-oncology at UC San Francisco. ... impacting the development of new treatments and advancing strategies to minimize treatment side effects ...
(Date:7/23/2015)... ... July 23, 2015 , ... The Pittcon 2016 Program Committee ... Mosher Professor of Chemistry and Professor, by courtesy, of Applied Physics at Stanford University, ... in Solids Led to Super-Resolution Nanoscopy in Cells and Beyond” , Dr. Moerner’s ...
Breaking Biology Technology:Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 23SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 2The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 3
... US - A team of Bioengineers in the United ... its ability to produce ethanol. The research, published in ... metabolic engineering can be combined for strain improvement, a ... focused their research on Zymomonas mobilis, a bacterium noted ...
... NEW YORK, Dec. 10, 2010 Ramius V&O Acquisition ... announced that it has sent a letter to the ... CYPB ) outlining its willingness to acquire all ... for $5.50 per share.  The offer is conditioned upon ...
... new hand-held medical device will help UK athletes reach ... sporting competitions. UK Sport, the UK,s high performance sports ... organisation to use cutting edge technology developed by Argento ... athletes will be able to monitor various proteins which ...
Cached Biology Technology:Bioengineers develop bacterial strain to increase ethanol biofuel production 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6Medical science helps UK athletes reach peak performance 2Medical science helps UK athletes reach peak performance 3
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... University Medical Center, Chicago, and Ceregene Inc., San Diego, ... and stop the anatomic, cellular changes that occur in ... is the first study to demonstrate that, using this ... mice with this treatment. , Results of the ...
... The Hospital for Sick Children (SickKids) and the University of ... can create neural cell types that can be transplanted into ... reported in the June 14, 2006 issue of The Journal ... of cells can be made from these stem cells (called ...
... that go on to form the face, skull and ... is determined much earlier in development than previously thought, ... according to a recent study published in the journal ... with three different technologies -- immunostaining of proteins, in ...
Cached Biology News:Gene therapy injected into the brains' of mice with Huntington's disease 2Gene therapy injected into the brains' of mice with Huntington's disease 3Gene therapy injected into the brains' of mice with Huntington's disease 4Stem cells found in adult skin can be transplanted and function in mouse models of disease 2Making a face: A new and earlier marker of neural crest development 2
NATIVE RAT OSTEOCALCIN...
... W x H): 17 3/4" x ... 12 slidesTime: Programmable 0 - 100 hoursControl: ... hybridization steps 40 user programmable protocols 3 ... temperature) Rapid temperature ramp-up from 37 - ...
Defender against cell death 1...
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
Biology Products: